The CANNHEART study is focused on exploring the relationship between cannabis use and heart health in individuals living with HIV. Participants will be grouped based on their self-reported cannabis use patterns (e.g., blunts, joints, vapes, or non-use) and urine toxicology results. The study aims to better understand how these factors may influence cardiovascular health outcomes in people living with HIV.
What is involved?
- There will be 3 visits for patients who use cannabis. The first 2 visits lasting about an hour, there will be blood and urine collection. The 3rd visit lasts about 3 hours, there will also be blood and urine collection plus an arterial ultrasound plus a heart MRI.
- There will be 2 visit for patients who do not use cannabis. The first visit lasting about an hour, there will be blood and urine collection. The 2nd visit lasts about 3 hours, there will also be blood and urine collection plus an arterial ultrasound plus a heart MRI.
The study includes careful monitoring and controls for factors such as age, sex, race/ethnicity, and co-existing conditions like hypertension, dyslipidemia, and substance use to ensure balanced and accurate analyses.
Yes. The study has been reviewed and approved by the Institutional Review Board (IRB) to ensure that all procedures are ethical and prioritize participant safety.
No. We are also seeking individuals who have not recently used cannabis.
The University of Miami Miller School of Medicine.
Yes. Participants will receive up to $250 as compensation for their time and effort, distributed upon the completion of study milestones.
Your participation could provide essential insights into the health of the HIV+ community. Contact us today to learn more and join the study!
